<table>
<thead>
<tr>
<th>Manuscript Number:</th>
<th>PIDJ-216-716</th>
</tr>
</thead>
<tbody>
<tr>
<td>Full Title:</td>
<td>Linezolid for children with tuberculous meningitis: more evidence required.</td>
</tr>
<tr>
<td>Article Type:</td>
<td>Letter to the Editor</td>
</tr>
<tr>
<td>Keywords:</td>
<td>Tuberculosis, Meningitis, Linezolid</td>
</tr>
</tbody>
</table>
| Corresponding Author: | Robindra Basu Roy, MRCPCH  
|                   | Imperial College London  
|                   | London, UNITED KINGDOM |
| Corresponding Author Secondary Information: | |
| Corresponding Author's Institution: | Imperial College London |
| Corresponding Author's Secondary Institution: | |
| First Author:    | Robindra Basu Roy, MRCPCH |
| First Author Secondary Information: | |
| Order of Authors: | Robindra Basu Roy, MRCPCH  
|                   | James A Seddon, PhD |
| Order of Authors Secondary Information: | |
| Manuscript Region of Origin: | UNITED KINGDOM |
Linezolid for children with tuberculous meningitis: more evidence required

Robindra Basu Roy, MRCPCH & James A. Seddon, PhD

Department of Academic Paediatrics
Imperial College London

Corresponding Author:

Dr. R. Basu Roy
Department of Academic Paediatrics
2nd Floor, Medical School Building
St. Mary’s Campus
Imperial College London
Norfolk Place
London
W2 1PG
United Kingdom

r.basu-roy@imperial.ac.uk
Tel: +4420 7594 8839
Fax: +4420 7594 3984

Funding:

R Basu Roy is a Clinical Research Training Fellow jointly funded by the UK Medical Research Council (MRC) and the UK Department for International Development (DFID) under the MRC/DFID Concordat agreement and this funding is also part of the EDCTP2 programme supported by the European Union. (MR/K023446/1).

JA Seddon is an Academic Clinical Lecturer funded by the National Institute of Health Research, and also the recipient of a Starter Grant from the Academy of Medical Sciences (AMS-SGCL11-Seddon).

Conflicts of Interest: None.

Keywords: Linezolid, Tuberculosis, Meningitis

A Letter to the Editor in response to:

To the editors:

Tuberculous meningitis (TBM) is a devastating disease. With the currently available treatment regimens one in five children die and only a third of surviving children escape neurological sequelae. If there was any way of improving these outcomes significant mortality and morbidity would be averted. We were greatly interested, therefore, to read the study by Li et al regarding the use of linezolid in children with TBM in Beijing.

In many ways linezolid is an attractive therapeutic option given its good bioavailability, excellent CSF penetration and proven efficacy against M. tuberculosis. However, three major obstacles currently limit the use of linezolid in the treatment of pediatric TBM: efficacy, safety and current high cost. Until this report the only described use of linezolid in pediatric TBM had been in the successful treatment of a South African case of extensively drug-resistant TBM.

Caution is warranted in interpreting the efficacy of linezolid in the treatment of pediatric TBM from this report. The retrospective design, unrandomised nature of group allocations, and unblinded ascertainment of outcomes limit how much can be inferred. In terms of patient selection, children were given linezolid if they remained febrile after two weeks on conventional treatment and had no neurological improvement in that time. It is therefore unclear why over 50% of children in the control group had a fever clearance time of greater than 4 weeks. It would be useful for the authors to further clarify on what criteria the decision to use linezolid was made, and from what common reference point during therapy fever clearance time
comparisons were made. Persistent fever following initiation of anti-tuberculous therapy with confirmed drug susceptible strains of *M. tuberculosis* is a recognized, although unusual, clinical phenomenon.4

It would also be important to know if the improved outcomes were due to linezolid improving the treatment of TBM generally, or if the advantage was the result of improved treatment in cases with drug resistance. Understanding this would allow clinicians to evaluate whether this drug should be reserved only for cases with drug resistance. It would therefore be interesting to know if there are any molecular or phenotypic drug resistance results available from either the 14 microbiologically confirmed TB cases, or from the TB source cases identified in 50 of the children.

Regarding safety, the authors report no significant difference in adverse events (GI disturbance, hepatotoxicity, rash, peripheral neuropathy or thrombocytopenia) between the 36 children treated with linezolid and those who received standard treatment. However, it is unclear from the report how the children were evaluated for these and whether they may have experienced any other side effects (such as lactic acidosis, optic neuropathy, impaired renal function, raised amylase or hypoglycemia5).

We commend the authors on reporting these cases and providing some much-needed data where so little exists. We look forward to learning from their experiences in even more depth. In our opinion however, there is currently still insufficient evidence to warrant use of linezolid in paediatric TBM without information strongly suggestive of drug resistance.


